Enochian Biosciences, Inc.
ENOB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $4,165 | $0 |
| G&A Expenses | $0 | $0 | $15,318 | $0 |
| SG&A Expenses | $0 | $0 | $15,318 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $19,073 | $0 |
| Operating Expenses | $0 | $0 | $38,557 | $0 |
| Operating Income | -$0 | -$0 | -$38,557 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | -$1,127 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$39,684 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$39,684 | -$0 |
| % Margin | – | – | – | – |
| EPS | -1.08 | -0.84 | -705,301.71 | -2.16 |
| % Growth | -28.6% | 100% | -32,652,756.9% | – |
| EPS Diluted | -1.08 | -0.84 | -705,301.71 | -2.16 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | -$0 | -$580 | $0 |
| Depreciation & Amortization | $0 | $0 | $113 | $124 |
| EBITDA | -$0 | -$0 | -$40,151 | -$113,683 |
| % Margin | – | – | – | – |